Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 302

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 302
---
 other diagnostic platforms, such as imaging and/or blood protein biomarkers. |

DiamiR’s tests are currently not commercially available. If the tests are successfully developed and launched, DiamiR believes that it will compete primarily on the basis of:

| ● | Clinical validation of DiamiR’s biomarker panels using                                                                                    
 samples from large heterogeneous cohorts from both retrospective and prospective clinical studies, including demonstration of correlation 
 of DiamiR’s biomarkers with currently used biomarkers of AD and of the ability of DiamiR’s tests to specifically identify                 
 AD, and differentiate it from other NDs;                                                                                                  |

| ● | DiamiR’s ability to identify MCI, and predict whether 
 a patient is likely to progress to AD or other NDs;   |

| ● | DiamiR’s ability to monitor disease progression and 
 response to treatment;                              |

| ● | Ease of use of DiamiR’s tests: they are minimally invasive, 
 based on analysis of plasma;                                |

| ● | Potential cost advantage of DiamiR’s tests compared        
 to imaging and analysis of cerebrospinal fluid biomarkers; |

| ● | DiamiR’s collaborations with high profile academic clinical 
 centers; and                                                |

| ● | Value to customers (e.g. asymptomatic subjects in high-risk 
 groups) promoting repeat testing (e.g. annual screening).   |

DiamiR believes that its success will depend on its ability to expeditiously:

| ● | Launch the tests in the US and expand in countries outside 
 of the US;                                                 |

| ● | Continue to innovate and maintain scientifically advanced 
 technology;                                               |

| ● | Market and sell DiamiR’s tests, initially as a clinical    
 research tool for pre-selection of patients for AD trials; |

| ● | Expand DiamiR’s tests to provide information on other 
 NDs;                                                  |

| ● | Optimize DiamiR’s sample collection process; |

| ● | Publish clinical studies in peer-reviewed journals; |

| ● | Continue to validate DiamiR’s tests, especially with 
 respect to treatment benefit;                        |

| ● | Attract and retain skilled personnel; |

| ● | Protect DiamiR’s products and technology with patents; |

| ● | Assure the quality of DiamiR’s LDTs produced under FDA 
 and CLIA guidelines;                                   |

| ● | Assure that the CLIA lab where tests are produced continue 
 to maintain all appropriate licenses; and                  |

| ● |